Peterson Amy C.
Officer at EXEL; EVP, Chief Development Officer at CTMX; CMO, Immuno-oncology at BGNE
- Sold, on record
- $12.1M
- Dollars the filings state
- Form 4 sales
- 7
- Latest May 16, 2025
- Form 144 notices
- 1
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale BGNEUnusualNov 13, 2017 2017
Sold 3,601 shares at $82.96 ($299k)
Peterson Amy C., CMO, Immuno-oncology
Sold 100% of holdings ($299k position)0 shares leftFirst sale on recordFiling
- 2 Form 4 sale BGNEUnusualAug 23, 2018 +283 days
Sold 5,769 shares at $169.12 ($976k)
Peterson Amy C., CMO, Immuno-oncology
Sold 100% of holdings ($976k position)0 shares leftFiling
- 3 Form 4 sale BGNEUnusualNov 12, 2018 +81 days
Sold 40,000 shares at $120.20 ($4.8M)
Peterson Amy C., CMO, Immuno-oncology
Sold 100% of holdings ($4.8M position)0 shares leftFiling
- 4 Form 4 sale BGNEUnusualDec 18, 2018 +36 days
Sold 20,000 shares at $133.68 ($2.7M)
Peterson Amy C., CMO, Immuno-oncology
Sold 100% of holdings ($2.7M position)0 shares left3.5x usual sizeFiling
- 5 Form 4 sale CTMXPlan not statedJul 20, 2022 +1310 days
Sold 7,463 shares at $1.42 ($11k)
Peterson Amy C., EVP, Chief Development Officer
Sold 10.6% of holdings ($100k position)62,690 shares leftFirst sale on recordFiling
- 6 Form 4 sale CTMXNo planMar 16, 2023 +239 days
Sold 4,257 shares at $1.98 ($8k)
Peterson Amy C., EVP, Chief Development Officer
No 10b5-1 planSold 6.8% of holdings ($124k position)58,433 shares leftFiling
- 7 Form 144 notice EXELNoticeMay 16, 2025 +792 days
Filed to sell 72,776 shares ($3.4M)
Peterson Amy C., Officer
10b5-1 planFirst sale on recordFiling
- 8 Form 4 sale EXELNo planMay 16, 2025 same day
Sold 72,776 shares at $45.47 ($3.3M)
Peterson Amy C., EVP Prod Dev & Med Aff & CMO
No 10b5-1 planSold 13.5% of holdings ($24.5M position)465,393 shares leftFirst sale on recordFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (8)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | May 16, 2025 | EXEL | EVP Prod Dev & Med Aff & CMO | Form 4 sale | 72,776 | $3.3M | 13.5% | No plan | SEC |
| May 16, 2025 | May 16, 2025 | EXEL | Officer | Form 144 notice | 72,776 | $3.4M | Notice | SEC | |
| Mar 16, 2023 | Mar 20, 2023 | CTMX | EVP, Chief Development Officer | Form 4 sale | 4,257 | $8k | 6.8% | No plan | SEC |
| Jul 20, 2022 | Jul 21, 2022 | CTMX | EVP, Chief Development Officer | Form 4 sale | 7,463 | $11k | 10.6% | Plan not stated | SEC |
| Dec 18, 2018 | Dec 19, 2018 | BGNE | CMO, Immuno-oncology | Form 4 sale | 20,000 | $2.7M | 100.0% | Unusual | SEC |
| Nov 12, 2018 | Nov 13, 2018 | BGNE | CMO, Immuno-oncology | Form 4 sale | 40,000 | $4.8M | 100.0% | Unusual | SEC |
| Aug 23, 2018 | Aug 24, 2018 | BGNE | CMO, Immuno-oncology | Form 4 sale | 5,769 | $976k | 100.0% | Unusual | SEC |
| Nov 13, 2017 | Nov 15, 2017 | BGNE | CMO, Immuno-oncology | Form 4 sale | 3,601 | $299k | 100.0% | Unusual | SEC |